To clarify the preventive effect of taurohyodeoxycholic acid on liver cholestasis induced by toxic bile acids in rats, we evaluated whether modulation of cytochrome P4503A-linked oxidases is involved in the hepatic bile acid retention and secretion mechanism. We investigated whether the safe or the toxic taurochenodeoxycholic acid, administered singly or together, affects cytochrome P450-catalyzed drug metabolism or biliary parameters. We also considered whether the inhibition of the P-glycoprotein export pump by vinblastine might be related to cytochrome P4503A overexpression.
Methods
Hydroxylation of testosterone and N-demethylation of aminopyrine were studied in subcellular rat liver preparations after intravenous infusion of hepatoprotective and toxic bile acids administered singly or together. Bile flow, calcium secretion, biliary enzymes activity, and secretion rates of the endogenous and administrated bile acids were determined. CYP3A-dependent monooxygenases were also measured in the same coinfusion model in the presence of vinblastine.
Results
Although wide modulation of the activities of different P450 subfamily of isoenzymes was seen, P4503A-associated monooxygenases showed similar patterns in the various situations, ie, induction by taurohyodeoxycholic acid, reduction by taurochenodeoxycholic acid, and protection (intermediate induction) in the coinfusion experiments. This correlates well with biliary parameters demonstrating the hepatoprotective ability of taurohyodeoxycholic acid. Coadministration of bile acids and vinblastine significantly modifies CYP3A-linked activities.
Conclusions
Bile acid structure seems to be linked with hepatotoxicity/hepatoprotection and P4503A modulation. Taurohyodeoxycholic acid could be therapeutic in cholestatic liver disease by inducing P4503A; we can hypothesize that an associated P-glycoprotein expression might facilitate biliary excretion of toxic taurochenodeoxycholic acid accumulated in the liver during cholestasis.
RodaA, PiazzaF, BaraldiniM, SperoniE, GuerraMC, CerrC, Cantelli-FortiG. Taurohyodeoxycholic acid protects against taurochenodeoxycholic acid-induced cholestasis in the rat. Hepatology1998;27: 520–5.
2.
KitaniK, OhtaM, KanaiS. Tauroursodeoxycholate prevents biliary protein excretion induced by other bile salts in the rat. Am J Physiol1985;248:G407–G417.
3.
KitaniK, KanaiS, SatoY, OhtaM. Tauro a-muricholate is as effective as Tauro β-muricholate and tauroursodeoxycholate in preventing the hepatocyte damage caused by continuous infusion of taurochenodeoxycholate in the rat. Hepatology1994;19:1011–12.
4.
KanaiS, KitaniK. Glycoursodeoxycholate is as effective as taurochenodeoxycholate in preventing the taurocholate-induced cholestasis in the rat. Res Commun Chem Pathol Pharmacol1983;42:423–30.
5.
RodaA, PellicciariR, PolimeniC, CerréC, Cantelli FortiG, SadeghpourB, SapigniE, . Metabolism, pharmacokinetics, and activity of a new 6-fluoro analogue of ursodeoxycholic acid in rats and hamsters. Gastroenterology1995;108:1204–14.
6.
RodaA, CerréC, ManettaAC, CainelliG, Umani-RonchiA, PanunzioM. Synthesis and physicochemical, biological and pharmacological properties of new bile acids amidated with cyclic amino acids. J Med Chem1996;39:2270–6.
7.
RodaA, HofmannAF, MyselsKJ. The influence of bile salt structure on self association in aqueous solutions. J Biol Chem1983; 258:6362–70.
8.
RodaA, MinutelloA, AngelottiMA, FiniA. Bile acids structure-activity relationship: evaluation of bile acid lipophilicity using 1-octanol/water partition coefficient and reverse phase HPLC. J Lipid Res1990; 31:1433–43.
9.
KitaniK, KanaiS, OhhtaM. Tauroursodeoxycholate prevents taurocholate-induced cholestasis in the rat. Life Sci1982;30:515–23.
10.
Sawkat AnwerM, EngelkingLR, NolanK, SullivanD, ZimniakP, LesterR. Hepatotoxic bile acids increase cytosolic Caβ+ activity of isolated rat hepatocytes. Hepatology1988;8:887–91.
11.
CombettesL, BerthonB, DoucetE, ErlingerS. Characteristics of bile acid-mediated Caβ+ release from permeabilized liver cells and liver microsomes. J Biol Chem1989;264:157–67.
12.
SchmuckerDL, OhtaM, KanaiS, SatoY, KitaniK. Hepatic injury induced by bile salts: correlation between biochemical and morphological events. Hepatology1990;12:1216–21.
13.
WardA, BrogdenAN, HeelRC, SpeightTM, AveryGS. Ursodeoxycholic acid: a review of its pharmacological properties and therapeutic efficacy. Drugs1984;27:95–131.
14.
KaplanMM, RighettiA. Induction of rat liver alkaline phosphatase: the mechanism of the serum elevation in bile duct obstruction. J Clin Invest1970;49:508–16.
15.
KaplanMM, OnkuboA, QuaroniEG, Sze-TuD. Increased synthesis of rat liver alkaline phosphatase by bile duct ligation. Hepatology1983;3:433–9.
16.
GurantzD, SchteingartCD, HageyLR, SteinbachJH, GrotmolT, HofmannAF. Hypercholeresis induced by unconjugated bile acids infusion correlates with recovery in bile of unconjugated bile acids. Hepatology1991;13:340–50.
17.
SalphatiL, BernetLZ. Modulation of P-glycoprotein expression by cytochrome P450 inducers in male and female rat livers. Biochemical Pharmacol1998:55:387–95.
18.
GottesmanMM, PastanI. Biochemistry of multidrug resistence mediated by the multidrug transporter. Annu Rev Biochem1993;62: 385–427.
19.
ChinKV, PastanI, GottesmanMM. Function and regulation of the human multidrug transporter. Adv Cancer Res1993;60:157–80.
20.
LeveilleWC, AriasIM. The biology of the P-glycoproteins. J Membr Biol1995;143:89–102.
21.
BorstP, SchinkelAH, SmitJJ, WagenaarE, Van DeemterL, SmithAJ, EijdemsEW, BaasF, ZamanGJ. Classical and novel forms of multidrug resistence and the physiological functions of P-glycoproteins in mammals. Pharmacol Ther1993;60:289–99.
22.
UedaK, OkamuraN, HiraiM, TanigawaraY, SaekiT, KiokaN, KomanoT, HoriR. Human P-glycoprotein transports cortisol, aldosterone and dexamethasone, but not progesterone. J Biol Chem1992;267: 24248–52.
23.
FordJM, HaitWN. Pharmacologic circumvention of multidrug resistance. Cytotechnology1993;12:171–212.
24.
DevaultA, GrosP. Two members of the mouse mdr gene family confer multidrug resistence with overlapping but distinct drug specificities. Mol Cell Biol1990;19:1652–63.
25.
GerloffT, StiegerB, HagenbuchB, MadonJ, LandmannL, RothJ, HofmannAF, MeierP. The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J Biol Chem1998;273:10046–50.
26.
AccatinoL, PizarroM, SolisN, KoenigCS, VollrathV, ChianaleJ. Modulation of hepatic content and biliary excretion of P-glycoprotein in hepatocellular and obstructive cholestasis in rat. J Hepatol1996;25: 349–61.
27.
SmitWJ, DuinE, SteenH, OostingR, RoggeveldJ, MeijerDKF. Interactions between P-glycoprotein substrates and other cationic drugs at the hepatic excretory level. Br J Pharm1998;123:361–70.
28.
PaoliniM, PozzettiL, PedulliGF, CipolloniM, MesircaR, Cantelli-FortiG. Paramagnetic resonance in detecting carcinogenic risk from cytochrome P450 overexpression. J Investig Med1996;44:470–3.
29.
PaoliniM, BaroneM, CorsiC, PaganinC, RevoltellaRP. Expression and inducibility of drug-metabolising enzymes in novel murine liver epithelial cell lines and their ability to activate procarcinogens. Cancer Res1991;51:301–9.
30.
MazelP. Fundamentals of drug metabolism and drug disposition. LadoB, MahdelHG, WayEL, eds. Baltimore: Williams and Wilkins, 1971:546–50.
31.
NashT. Colorimetric estimation of formaldehyde by means of Hantzsch reaction. Biochem J1953;55:416–21.
32.
PaoliniM, MesircaR, PozzettiL, SaponeA, Cantelli-FortiG. Induction of CYP 2B1 mediated pentoxyresorufin O-dealkylase activity in different species, sex and tissue by prototype 2B1-inducers. Chem Biol Interact1995;95:127–39.
33.
PlattJ, MolitorE, DoehmerJ, DograS, OeschF. Genetically engineered V79 Chinese hamster cell. Expression of purified cytochrome P4502B1 monooxygenase activity. Biochem Toxicol1989;4:1–5.
34.
Van der HoevenTH. Assay of hepatic microsomal testosterone hydroxylases by high-performance liquid chromatography. Anal Biochem1984;138:57–65.
35.
PaoliniM, PozzettiL, SaponeA, BiagiGL, Cantelli-FortiG. Development of basal and induced testosterone hydroxylase activity in the chicken embryo in ovo. Br J Pharmacol1997;122:344–50.
36.
ChungWA, ChaYN. Oxidation of caffeine to theobromine and theophillyne is catalyzed primarily by flavin-containing monooxygenase in liver microsomes. Biochem Biophys Res Comm1997;235:685–8.
37.
LowryOH, RosenbroughHJ, FarrAL, RandallRJ. Protein measurement with folin phenol reagent. J Biol Chem1951;193:265–75.
38.
BaileyYL. Techniques in protein chemistry. Amsterdam: Elsevier, 1967:340–1.
39.
BoxGEP, HunterWG. Statistics for experiments. Wiley: New York, 1978: 80–82.
40.
LaemmliUK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature1970;227:680–5.
41.
TowbinH, StachelinT, GordonJ. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA1979;76:4350–4.
42.
DuttonDR, ReedGA, ParkinsonA. Redox cycling of resorufin catalyzed by rat liver microsomal NADPH-cytochrome P450 reductase. Arch Biochem Biophys1989;268:605–16.
43.
FausaO. Quantitative determination of serum bile acids using a purified 3a dehydrogenase. Scand J Gastroenterol1975;10:747–51.
44.
RodaA, FestiD, SamaC, MazzellaG, AldiniR, RodaE, BarbaraL. Enzymatic determination of cholesterol in bile. Clin Chim Acta1975:64:337–41.
45.
RodaA, GerminianiS, RossiR, FestiD, RodaE, BarbaraL. Enzymatic determination of phospholipids in bile. Lab J Res Med1981; 2:119–22.
46.
RossiSS, ConverseJL, HofmannAF. High pressure liquid chromatographic analysis of conjugated bile acids in human bile: simultaneous resolution of sulfated and unsulfated lithocholyl amidates and the common conjugated bile acids. J Lipid Res1987;28:589–95.
47.
RodaA, GioacchiniAM, CerréC, BaraldiniM. High-performance liquid chromatographic-electrospray mass spectrometric analysis of bile acids in biological fluids. J Chromatogr1995;665: 281–94.
48.
LoriaP, BozzoliM, AngelicoM, BertolottiM, CarubbiF, ConcariM, BaiocchiL,. Effect of taurohyodeoxycholic acid on biliary lipid secretion in man: preliminary report. Ital J Gastroenterol1996:28:391–2.
49.
ShimadaT, YamazakeH, MimuraM, InuiY, GuengerichFP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther1994;270:414–23.
50.
WatkinsPB, WrightonSA, SchuetzFG, MolowaDT, GuzelianPS. Identification of glucocorticoid-inducible cytochromes P450 in the intestinal mucosa of rats and man. J Clin Invest1987;80: 1029–36.
51.
JamesP, WhitlockJR, DenisonMS. Induction of cytochrome P450 enzymes that metabolize xenobiotics. In: Ortiz de MontellanoPR, ed. Cytochrome P450: structure, mechanism, and biochemistry. 2nd ed. New York: Plenum Press, 1995:367.
52.
BrownPG, ThorgeirssonSS, SilvermannYA. Cloning and regulation of the rat MDR2 gene. Nucleic Acids Res1993;21:3885–91.
53.
VolmM, MatternJ, PmmerenkeEW. Lime course of mdr gene amplification during in vivo selection for dexorubicin-resistence and during reversed in murine leukemia L1210. Anticancer Res1991;11: 579–85.
54.
ArayaZ, HellmanU, HanssonR. Characterisation of taurochenodeoxycholic acid 6 alpha-hydroxylase from pig liver microsomes. Eur J Biochem1995;231:855–61.
55.
MazzantiR, FantappiéO, KamimotoY, GatmaitanZ, GentiliniP, AriasIM. Bile acid inhibition of P-glycoprotein mediated transport in multidrug resistant cells and rat liver canalicular membrane vesicles. Hepatology1993;20:170–6.
56.
KamimotoY, GatmaitanZ, HsuJ, AriasIM. The function of GP170, the multidrug resistence gene product, in rat liver canalicular membrane vesicles. J Biol Chem1989;264:11693–8.
57.
ErlingerS. Do intracellular organelles have any role in transport of bile acids by hepatocytes?J Hepatol1996;24(suppl):88–93.
58.
ChenJ, FarrellGC. Bile acids produce a generalized reduction of the catalytic activity of cytochromes P450 and other hepatic microsomal enzymes in vitro: relevance to drug metabolism in experimental cholestasis. J Gastoenterol Hepatology1996;11:870–7.
